What is the appropriate starting dose of AndroFeme (testosterone) 1% gel for a female patient with a serum testosterone level of 20 ng/dL?

Starting Dose of AndroFeme 1% for Female with Testosterone Level of 20 ng/dL

Begin with 5 mg of testosterone gel applied daily to the upper arm or outer thigh, aiming to restore serum testosterone to the mid-to-high premenopausal range of 30–50 ng/dL. 1

Indication Confirmation

• Testosterone therapy in women is evidence-based only for treating hypoactive sexual desire disorder (HSDD) in postmenopausal women after a formal biopsychosocial assessment. 1
• Do not prescribe testosterone for bone health, cognitive function, energy, general well-being, or metabolic dysfunction, as efficacy and long-term safety data are lacking for these indications. 1
• Absolute contraindications include pregnancy, hormone-sensitive breast or uterine cancer, and active cardiovascular disease. 1

Formulation and Dosing

• AndroFeme 1% gel (or any male-approved transdermal testosterone gel used off-label) should be initiated at 5 mg daily applied to the upper arm or outer thigh. 1
• This dose corresponds to approximately 0.5 mL of a 1% gel (which contains 10 mg testosterone per mL), delivering 5 mg of testosterone per application. 2
• The patient's baseline testosterone of 20 ng/dL is below the target premenopausal range; the 5 mg daily dose is designed to restore levels to 30–50 ng/dL. 1
• Apply the gel to clean, dry, intact skin; allow it to dry for a few minutes before dressing, and wash hands immediately after application to prevent transfer. 2

Baseline Assessment

• Obtain a baseline total testosterone measurement before starting therapy (already done: 20 ng/dL). 1
• Document the presence of HSDD symptoms (distressing low sexual desire, reduced frequency, receptivity, and initiation). 1

Initial Follow-Up (3–6 Weeks)

• Repeat total testosterone 3–6 weeks after initiation to verify absorption and guide dose adjustment. 1
• Target serum total testosterone of 30–50 ng/dL; if the level remains below 30 ng/dL, increase the dose in 2.5 mg increments (e.g., to 7.5 mg daily). 1
• If the level exceeds 50 ng/dL, reduce the dose to prevent supraphysiologic exposure and androgen excess. 1

Long-Term Monitoring (Every 6 Months)

• Evaluate clinical response (improvement in sexual desire, frequency, receptivity, and initiation) and screen for signs of androgen excess (acne, hirsutism, voice deepening, clitoromegaly) with concurrent serum testosterone measurement. 1
• Discontinue therapy if no clinical benefit is observed by 6 months, as prolonged exposure without benefit is unjustified. 1
• Continue monitoring serum testosterone every 6 months to detect overuse and ensure levels remain within the physiologic premenopausal range. 1

Safety Considerations

• Clinical trials of up to 24 months have shown that physiologic-dose testosterone in postmenopausal women is not associated with serious adverse events. 1
• Evidence beyond 24 months is lacking; long-term effects on cardiovascular health, cancer risk, and cognition remain unknown. 1
• Hematocrit monitoring is not required for women receiving these low doses, unlike in male patients. 1

Common Pitfalls to Avoid

• Do not use male-formulated testosterone gels at typical male doses (50–100 mg daily); this yields supraphysiologic testosterone levels in women and raises the risk of irreversible virilization. 1
• Do not continue therapy beyond 6 months without documented improvement in sexual function. 1
• Do not prescribe compounded "bioidentical" testosterone preparations unless no authorized equivalent exists, as efficacy and safety data are insufficient. 1
• Do not use supraphysiologic delivery methods such as pellets or intramuscular injections, as they produce excessive testosterone levels that cannot be easily adjusted. 1